$ARE

ALEXANDRIA REAL ESTATE EQUITIES, INC. (ARE): Results of Operations and Financial Condition

ALEXANDRIA REAL ESTATE EQUITIES, INC. (ARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26ex991supp.htm EX-99.1 2Q26 EX 99.1 SUPP Alexandria Real Estate Equities, Inc. All Rights Reserved . © 2026 Alexandria Real Estate Equities, Inc. All Rights Reserved . © 2026 Table of Contents June 30, 2026 COMPANY HIGHLIGHTS Page Page Alexandria's Mission and Clust

Original reporting
Published Aug 3, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ARE
Neutral
low confidence
Mentioned
$ARE
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ARENeutralLow
01

Why it matters

The attached materials are designed to update investors on financial results, guidance, balance sheet and credit metrics, and operating performance (occupancy, leasing, construction pipeline). Those inputs typically drive REIT valuation and rate/credit sensitivity trades.

02

Market read

This is a company-specific earnings disclosure that can move ARE via guidance and operating/credit metrics, with the next catalyst being the Aug 4 earnings call.

03

What to watch

Traders will likely focus on guidance details, same-property performance, leasing spreads, contractual expirations, and key credit metrics, none of which are actually shown in the provided text.

Relevance 7/10Novelty 3/10Timing: Filed Aug 3, 2026, ahead of the Aug 4, 2026 2:00 p.m. ET earnings call.

Background

The filing is an SEC Form 8-K, Item 2.02, attaching an earnings press release supplement for Alexandria Real Estate Equities’ second quarter ended June 30, 2026.

Company-level read

Ticker impact

$ARENeutralLow confidence
Context

ARE filed an 8-K with its 2Q26 results of operations and financial condition, plus guidance and operating metrics in the attached exhibit.

Expected impact

Likely modest-to-moderate volatility around the earnings release and the Aug 4, 2026 conference call, depending on guidance and occupancy/NOI trends.

Evidence & confidence

The provided scrape includes the filing structure and qualitative highlights but does not include the actual numeric results, guidance figures, or key credit metrics needed to forecast direction or magnitude.

Market effects

Life-science REIT demand and leasing momentum are reinforced by the company’s disclosed delivered R&D hub and long-term lease, but sector-wide read-through is limited without broader data.

No specific regional macro or market-wide data is provided in the scrape beyond company-level property/cluster framing.

Minimal, as the disclosure is company-specific and no cross-border financing or global regulatory items are included.

Counterpoint

Qualitative highlights (e.g., delivered facility, long-term lease) may not offset weaker occupancy, higher capex, or less favorable guidance if those are present in the missing numeric tables.

Key entities

  • Alexandria Real Estate Equities, Inc.

    Subject of the 8-K, reporting 2Q26 results and financial condition, with guidance and operating metrics in the exhibit.

  • Bristol Myers Squibb

    Named as the tenant for a delivered 426,927 RSF R&D facility under a 15-year lease referenced in the exhibit highlights.

Related articles

$AREMed

Alexandria Real Estate Equities, Inc. Reports 2Q26 and 1H26 Net (Loss) Income per Share - Diluted of $(0.43) and $1.68, respectively, and 2Q26 and 1H26 FFO per Share - Diluted, as Adjusted, of $1.73 a

Alexandria Real Estate Equities (NYSE: ARE) reported 2Q26 net loss per diluted share of $(0.43) and 2Q26 adjusted diluted FFO per share of $1.73, plus 1H26 net income per diluted share of $1.68. The company cited 2Q26 liquidity of $3.60B, a $5.0B credit line extended to 2032, and 2Q26 leasing volume of 1.04M RSF.

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.